AAAAAA

   
Results: 1-9 |
Results: 9
Three-year results of the Finnish prostate cancer screening trial
Authors: Maattanen, L Auvinen, A Stenman, UH Tammela, T Rannikko, S Aro, J Juusela, H Hakama, M
Citation: L. Maattanen et al., Three-year results of the Finnish prostate cancer screening trial, J NAT CANC, 93(7), 2001, pp. 552-553
Twelve-month treatment of overactive bladder - Efficacy and tolerability of tolterodine
Authors: Abrams, P Malone-Lee, J Jacquetin, B Wyndaele, JJ Tammela, T Jonas, U Wein, A
Citation: P. Abrams et al., Twelve-month treatment of overactive bladder - Efficacy and tolerability of tolterodine, DRUG AGING, 18(7), 2001, pp. 551-560
Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer
Authors: Isola, J Auvinen, A Poutiainen, M Kakkola, L Jarvinen, TAH Maattanen, L Stenman, UH Tammela, T Hakama, M Visakorpi, T
Citation: J. Isola et al., Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer, J UROL, 165(5), 2001, pp. 1569-1573
A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: Frequent HPCX linkage in families with late-onset disease
Authors: Schleutker, J Matikainen, M Smith, J Koivisto, P Baffoe-Bonnie, A Kainu, T Gillanders, E Sankila, R Pukkala, E Carpten, J Stephan, D Tammela, T Brownstein, M Bailey-Wilson, J Trent, J Kallioniemi, OP
Citation: J. Schleutker et al., A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: Frequent HPCX linkage in families with late-onset disease, CLIN CANC R, 6(12), 2000, pp. 4810-4815
Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen
Authors: Finne, P Auvinen, A Koistinen, H Zhang, WM Maattanen, L Rannikko, S Tammela, T Seppala, M Hakama, M Stenman, UH
Citation: P. Finne et al., Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen, J CLIN END, 85(8), 2000, pp. 2744-2747
5 alpha-reductase inhibitors
Authors: Tammela, T
Citation: T. Tammela, 5 alpha-reductase inhibitors, BENIGN PROSTATIC HYPERPLASIA: CURRENT THERAPY, 2000, pp. 27-37
Prospective randomized trial of interferon alfa-2a plus vinblastine versusvinblastine alone in patients with advanced renal cell cancer
Authors: Pyrhonen, S Salminen, E Ruutu, M Lehtonen, T Nurmi, M Tammela, T Juusela, H Rintala, E Hietanen, P Kellokumpu-Lehtinen, PL
Citation: S. Pyrhonen et al., Prospective randomized trial of interferon alfa-2a plus vinblastine versusvinblastine alone in patients with advanced renal cell cancer, J CL ONCOL, 17(9), 1999, pp. 2859-2867
European randomized study of prostate cancer screening: first-year resultsof the Finnish trial
Authors: Maattanen, L Auvinen, A Stenman, UH Rannikko, S Tammela, T Aro, J Juusela, H Hakama, M
Citation: L. Maattanen et al., European randomized study of prostate cancer screening: first-year resultsof the Finnish trial, BR J CANC, 79(7-8), 1999, pp. 1210-1214
Conservative treatments in men
Authors: Kondo, A Hedlund, H Siroky, M Awad, S Kapoor, R Nordling, J Tammela, T Yasuda, K
Citation: A. Kondo et al., Conservative treatments in men, INCONTINENCE, 1999, pp. 669-689
Risultati: 1-9 |